EWHIGH SIGNALFINANCIAL10-K

Edwards Lifesciences experienced a massive 74% decline in net income despite 11.5% revenue growth, indicating severe margin compression or extraordinary charges.

The dramatic disconnect between growing revenue and collapsing profitability suggests either significant one-time charges, operational inefficiencies, or fundamental business model challenges that require immediate investor attention. While operating cash flow surged 194%, the net income collapse represents a material deterioration in earnings quality that could signal underlying business stress.

Comparing 2026-02-25 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

Edwards Lifesciences shows mixed financial performance with revenue growing 11.5% to $6.1B and operating cash flow surging 194% to $1.6B, indicating strong operational cash generation. However, net income collapsed 74% from $4.2B to $1.1B despite revenue growth, while SG&A expenses increased 16.5% and liabilities expanded across current (+20.5%) and total (+12.3%) categories. This combination of declining profitability amid revenue growth and rising costs suggests either significant one-time charges or deteriorating operational efficiency that investors should scrutinize closely.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+194.2%
$542.3M→$1.6B

Operating cash flow surged 194.2% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
-74.3%
$4.2B→$1.1B

Net income declined 74.3% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
-22.9%
$1.2B→$893.4M

Buyback activity reduced 22.9% — capital being redeployed elsewhere or cash conservation underway.

Current Liabilities
Balance Sheet
+20.5%
$1.5B→$1.8B

Current liabilities rose 20.5% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+16.5%
$1.8B→$2.1B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Total Liabilities
Balance Sheet
+12.3%
$3.0B→$3.4B

Liabilities increased 12.3% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
+11.5%
$5.4B→$6.1B

Revenue growing 11.5% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-28
ADDED
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 7A.
These statements can sometimes be identified by the use of the forward-looking words such as may, believe, will, expect, project, estimate, should, anticipate, plan, goal, continue, seek, pro forma, forecast, intend, guidance, optimistic, aspire, confident, or other forms of these words or similar words or expressions or the negatives thereof.
Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as preliminary, initial, potential, possible, early feedback, or other forms of these words or similar words or expressions or the negatives thereof.
Unless otherwise indicated or otherwise required by the context, the terms we, our, it, its, Company, Edwards, and Edwards Lifesciences refer to Edwards Lifesciences Corporation and its subsidiaries.
+7 more — sign up free →
REMOVED
7262(b)) by the registered public accounting firm that prepared or issued its audit report .
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.
These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," or other forms of these words or similar words or expressions or the negatives thereof.
Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," "early feedback," or other forms of these words or similar words or expressions or the negatives thereof.
Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," "Edwards," and "Edwards Lifesciences" refer to Edwards Lifesciences Corporation and its subsidiaries.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →